Quantcast

Latest Shionogi Inc. Stories

2014-07-03 08:23:44

Begins July 4th and ends with a "Thunderclap" on first day of Menopause Awareness Month FLORHAM PARK, N.J. and CHICAGO, July 3, 2014 /PRNewswire/ -- Beginning July 4(th), women, men and health care providers are encouraged to lend their social voices to an often-neglected area of women's health by committing to have a conversation about sex after menopause in the doctor's office, at home or with friends. "For millions of women in America, sex after menopause is not a pleasurable,...

2014-01-13 08:30:09

FLORHAM PARK, N.J., Jan. 13, 2014 /PRNewswire/ -- Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote Brisdelle(TM) (paroxetine) capsules, 7.5 mg, the first and only non-hormonal prescription drug approved for the treatment of moderate to severe hot flashes associated with menopause. Under the terms of the agreement, Shionogi will promote Brisdelle, along with Osphena(TM) (ospemifene), its non-estrogen oral...

2011-07-25 08:00:00

CINCINNATI, July 25, 2011 /PRNewswire/ -- Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Mefenamic Acid Capsules, USP 250 mg, the Authorized Generic version of Ponstel(®). Prasco intends to begin shipping product immediately in the U.S. under the Prasco label. "With the introduction of the authorized generic of Shionogi's...

2011-05-09 07:00:00

FLORHAM PARK, N.J., May 9, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the publication in Pediatrics of data demonstrating the efficacy of non-stimulant KAPVAY(TM) (clonidine hydrochloride) extended-release tablets when combined with stimulant medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (6-17 years). This study, the first to evaluate KAPVAY in combination with...

2011-05-02 07:00:00

TARRYTOWN, N.Y., May 2, 2011 /PRNewswire/ -- ARMGO Pharma Inc., has appointed Dr. Sapan Shah as Chief Executive Officer, effective immediately. Dr. Shah joins ARMGO from Shionogi Inc., where he served as President and Chief Executive Officer since 2002. In addition to his role as CEO, Dr. Shah will also join ARMGO Pharma's Board of Directors. Dr. Shah commented: "I am very excited to be joining an organization of such high caliber as ARMGO Pharma Inc. The company has made tremendous...

2011-04-07 07:00:00

FLORHAM PARK, N.J., April 7, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA(TM) (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy. "Shionogi is proud to expand its mission of helping to bring high quality care to...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related